<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurol</journal-id>
<journal-title-group>
<journal-title>Journal of Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0340-5354</issn>
<issn pub-type="epub">1432-1459</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31119452</article-id>
<article-id pub-id-type="pmc">6647117</article-id>
<article-id pub-id-type="publisher-id">9363</article-id>
<article-id pub-id-type="doi">10.1007/s00415-019-09363-4</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurological Update</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An update on genetic frontotemporal dementia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Greaves</surname>
<given-names>Caroline V.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6155-8417</contrib-id>
<name>
<surname>Rohrer</surname>
<given-names>Jonathan D.</given-names>
</name>
<address>
<email>j.rohrer@ucl.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>Department of Neurodegenerative Disease, Dementia Research Centre, </institution><institution>UCL Queen Square Institute of Neurology, </institution></institution-wrap>Queen Square, London, WC1N 3BG UK </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>22</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>22</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<volume>266</volume>
<issue>8</issue>
<fpage>2075</fpage>
<lpage>2086</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>1</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Frontotemporal dementia (FTD) is a highly heritable group of neurodegenerative disorders, with around 30% of patients having a strong family history. The majority of that heritability is accounted for by autosomal dominant mutations in the chromosome 9 open reading frame 72 (<italic>C9orf72</italic>), progranulin (<italic>GRN</italic>), and microtubule-associated protein tau (<italic>MAPT</italic>) genes, with mutations more rarely seen in a number of other genes. This review will discuss the recent updates in the field of genetic FTD. Age at symptom onset in genetic FTD is variable with recently identified genetic modifiers including <italic>TMEM106B</italic> (in <italic>GRN</italic> carriers particularly) and a polymorphism at a locus containing two overlapping genes <italic>LOC101929163</italic> and <italic>C6orf10</italic> (in <italic>C9orf72</italic> carriers). Behavioural variant FTD (bvFTD) is the most common diagnosis in each of the genetic groups, although in <italic>C9orf72</italic> carriers amyotrophic lateral sclerosis either alone, or with bvFTD, is also common. An atypical neuropsychiatric presentation is also seen in <italic>C9orf72</italic> carriers and family members of carriers are at greater risk of psychiatric disorders including schizophrenia and autistic spectrum disorders. Large natural history studies of presymptomatic genetic FTD are now underway both in Europe/Canada (GENFI—the Genetic FTD Initiative) and in the US (ARTFL/LEFFTDS study), collaborating together under the banner of the FTD Prevention Initiative (FPI). These studies are taking forward the validation of cognitive, imaging and fluid biomarkers that aim to robustly measure disease onset, staging and progression in genetic FTD. Grey matter changes on MRI and hypometabolism on FDG-PET are seen at least 10 years before symptom onset with white matter abnormalities seen earlier, but the pattern and exact timing of changes differ between different genetic groups. In contrast, tau PET has yet to show promise in genetic FTD. Three key fluid biomarkers have been identified so far that are likely to be helpful in clinical trials—CSF or blood neurofilament light chain levels (in all groups), CSF or blood progranulin levels (in <italic>GRN</italic> carriers) and CSF poly(GP) dipeptide repeat protein levels (in <italic>C9orf72</italic> carriers). Increased knowledge about genetic FTD has led to more clinical presymptomatic genetic testing but this has not yet been mirrored in the development of either an accepted FTD-specific testing protocol or provision of appropriate psychological support mechanisms for those living through the at-risk phase. This will become even more relevant as disease-modifying therapy trials start in each of the genetic groups over the next few years.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Frontotemporal dementia</kwd>
<kwd>Neurogenetics</kwd>
<kwd>Tau</kwd>
<kwd>Progranulin</kwd>
<kwd>C9orf72</kwd>
<kwd>Biomarkers</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer-Verlag GmbH Germany, part of Springer Nature 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par2">Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder presenting with distinct changes in behaviour, language and motor function. Despite often being considered as a rare disease, FTD is probably the most common form of dementia experienced in people under the age of 60, with an estimated lifetime risk of 1 in 742 [<xref ref-type="bibr" rid="CR1">1</xref>]. The behavioural variant (bvFTD) is characterised by changes in personality, while the language variant (known as primary progressive aphasia, PPA) is typically associated with progressive speech production or comprehension difficulties [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. People with FTD can also develop motor deficits, either amyotrophic lateral sclerosis (FTD-ALS) or Parkinsonism, in the latter case often with specific features of a corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP) [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>].</p>
</sec>
<sec id="Sec2">
<title>Heritability, genes and phenotype</title>
<sec id="Sec3">
<title>Heritability</title>
<p id="Par3">FTD is a highly heritable disorder but almost uniquely within the neurodegenerative disease spectrum, it is neither purely genetic (like Huntington’s disease, HD) nor a mainly sporadic condition (like Alzheimer’s disease) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The extent of heritability of FTD has been the subject of a number of studies, with many of the initial investigations relying on the dichotomy between a ‘present’ or ‘absent’ family history. However, more nuanced family history scoring systems have been developed for FTD [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>] revealing a complex picture of heritability. Using the modified Goldman score [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] a strong family history [scores 1–3] was found in 31% [<xref ref-type="bibr" rid="CR8">8</xref>], whilst using the Penn score, an equivalent strong family history [high or medium categories] was found in 26% [<xref ref-type="bibr" rid="CR9">9</xref>]. All of these studies show variability in heritability across the clinical phenotypes, e.g. a strong family history has been found in 48% of people with bvFTD but only 12% of people with PPA [<xref ref-type="bibr" rid="CR9">9</xref>]. Heritability of the motor phenotypes is less clear (mainly due to small numbers in most studies), e.g. a strong family history has varied from 10 to &gt; 40% in FTD-ALS [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>The landscape of the frontotemporal dementia spectrum disorders. About 70% is sporadic with approximately equal numbers of TDP-43 proteinopathies and tauopathies (including corticobasal degeneration, <italic>CBD</italic> progressive supranuclear palsy, <italic>PSP</italic> Pick’s disease, <italic>GGT</italic> globular glial tauopathy), and a smaller number of FUSopathies (including atypical frontotemporal lobar degeneration with ubiquitin inclusions, aFTLDU). About 30% is genetic with TDP-43 proteinopathies being the commonest cause (mutations in <italic>C9orf72</italic> (usually TDP-43 types A or B), <italic>GRN</italic> (type A), <italic>TBK1</italic> (types A or B)<italic>, VCP</italic> (type D), <italic>SQSTM1,</italic> and <italic>TARDBP</italic>) then tauopathies (mutations in <italic>MAPT</italic>), FUSopathies (mutations in <italic>FUS</italic>) and other proteinopathies (mutations in <italic>CHMP2B</italic>)</p></caption><graphic id="MO1" xlink:href="415_2019_9363_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec4">
<title>Genes</title>
<p id="Par4">The majority of the heritability of FTD is accounted for by autosomal dominant mutations in three genes: progranulin (<italic>GRN</italic>), microtubule-associated protein tau (<italic>MAPT</italic>) and chromosome 9 open reading frame 72 (<italic>C9orf72</italic>) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Each genetic group causes between ~ 5 and 10% of all FTD, with geographical variability in different case series (e.g. a predominance in Northern Italy and the Basque country of <italic>GRN</italic> mutations [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]). Overall, <italic>C9orf72</italic> seems to be the most common worldwide cause of genetic FTD, followed by <italic>GRN</italic> and then <italic>MAPT</italic>. A list of pathogenic and other variants in these genes has been collated online in the AD&amp;FTD Mutation Database (<ext-link ext-link-type="uri" xlink:href="http://www.molgen.ua.ac.be/FTDmutations">http://www.molgen.ua.ac.be/FTDmutations</ext-link>): 79 <italic>GRN</italic> and 45 <italic>MAPT</italic> pathogenic variants are currently described. However, a Pubmed search of mutations reported over the last 5 years in these genes identifies a further 35 <italic>GRN</italic> and 18 <italic>MAPT</italic> pathogenic variants not included in that database, i.e. 114 <italic>GRN</italic> and 63 <italic>MAPT</italic> mutations currently identified in total. This number excludes the majority of missense variants in <italic>GRN</italic>, many of which may be risk factors for Alzheimer’s disease rather than a Mendelian cause of FTD, although identifying pathogenicity is not always easy [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p id="Par5">In recent years, mutations in an increasing number of genes have been associated with autosomal dominant FTD: <italic>VCP</italic> (2004), <italic>CHMP2B</italic> (2005), <italic>TARDBP</italic> (2008), <italic>FUS</italic> (2009), <italic>SQSTM1</italic> (2012), <italic>CHCHD10</italic> (2014), <italic>TBK1</italic> (2015), <italic>OPTN</italic> (2015), <italic>CCNF</italic> (2016), <italic>TIA1</italic> (2017). Cumulatively, they account for &lt; 5% of all FTD, with most only found in a small number of families across the world. Recent studies have identified <italic>TBK1</italic> as probably the fourth most common genetic cause overall of FTD, accounting for between 1 and 2% of all cases (although the pathogenic nature of many of the reported missense variants remains unclear [<xref ref-type="bibr" rid="CR17">17</xref>]). However, as with the major genetic groups, there is geographical variability: in a recent study of FTD in Sardinia, 8% of patients had a <italic>TARDBP</italic> mutation [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
</sec>
<sec id="Sec5">
<title>Age at onset</title>
<p id="Par6">Age at symptom onset is variable in each of the genetic forms of FTD, with intrafamilial variability (even within the same generation) of at least a decade in some families (particularly <italic>GRN</italic>). Whilst <italic>MAPT</italic> mutations are fully penetrant in most cases, both <italic>GRN</italic> [<xref ref-type="bibr" rid="CR19">19</xref>] and <italic>C9orf72</italic> [<xref ref-type="bibr" rid="CR20">20</xref>] mutations exhibit age-related penetrance with a small number of carriers in their 80s (and 90s) yet to develop symptoms. In both <italic>GRN</italic> and <italic>C9orf72</italic> carriers, <italic>TMEM106B</italic> has been identified as a genetic modifier, the association being stronger with <italic>GRN</italic> than with <italic>C9orf72</italic> [<xref ref-type="bibr" rid="CR21">21</xref>]: a lower age at onset in <italic>GRN</italic> may well be related to carrying the risk allele, with homozygous carriers of the protective allele rarely found in symptomatic <italic>GRN</italic> carriers, suggesting that this may be a factor in age-related penetrance [<xref ref-type="bibr" rid="CR22">22</xref>]. Another recently identified modifier of disease risk in <italic>GRN</italic> carriers, <italic>GFRA2</italic>, did not seem to affect age at onset [<xref ref-type="bibr" rid="CR22">22</xref>]. However, a study of <italic>C9orf72</italic> carriers identified a locus on chromosome six containing two overlapping genes (<italic>LOC101929163</italic> and <italic>C6orf10</italic>) in which a polymorphism at rs9357140 was associated with age of onset: median age of onset in GG carriers was 6 years earlier than AA carriers [<xref ref-type="bibr" rid="CR23">23</xref>]. The significance of the <italic>C9orf72</italic> repeat expansion length remains unclear, with no definitive evidence of an association with age of onset [<xref ref-type="bibr" rid="CR24">24</xref>]. Little is known about factors that modify age at onset in the <italic>MAPT</italic> group, although a recent study suggested that ApoE ε4 carriers had a lower age at onset in tauopathies including <italic>MAPT</italic> mutations [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
</sec>
<sec id="Sec6">
<title>Phenotype</title>
<p id="Par7">The most common clinical presentation of all genetic forms is bvFTD, but all phenotypes within the FTD spectrum are observed. <italic>MAPT</italic> mutation carriers may have prominent semantic impairment but that is rarely a presenting feature, nor are other forms of PPA; however, CBS and, in rare cases, PSP may both occur, although never FTD-ALS. In contrast, <italic>GRN</italic> mutations can present as a PPA syndrome, either a nonfluent variant of PPA or a mixed phenotype, not clearly fitting into one of the three described subtypes [<xref ref-type="bibr" rid="CR26">26</xref>]. CBS may occur either alone or in conjunction with PPA, but PSP and FTD-ALS are almost never seen. <italic>C9orf72</italic> expansion carriers may have an atypical neuropsychiatric presentation of bvFTD with associated hallucinations or delusions [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], and significantly, family members of <italic>C9orf72</italic> carriers have a greater risk of psychiatric disorders including autistic spectrum disorders, psychotic illnesses including schizophrenia, mood disorders and suicide [<xref ref-type="bibr" rid="CR27">27</xref>]. Unlike the other two major genetic groups, <italic>C9orf72</italic> expansions can cause FTD-ALS or ALS alone. PPA is a rare phenotype but is usually a nonfluent variant when present, and similarly parkinsonian disorders can occur but are infrequent as a presenting syndrome. Also unlike the other genetic groups, hyperkinetic movement disorders may occur, and <italic>C9orf72</italic> is said to be associated with a Huntington’s disease-like phenotype on some occasions [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
<p id="Par8">The phenotype in the other genetic groups is less clear. <italic>TBK1</italic> mutations can cause bvFTD, PPA, CBS, FTD-ALS and ALS alone—this unique combination within a single family can be particularly suggestive of a <italic>TBK1</italic> mutation. <italic>TBK1</italic> and <italic>TARDBP</italic> mutations can both be associated with focal temporal lobe atrophy and a semantic variant PPA [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], an unusual genetic FTD phenotype as this variant of PPA is almost always sporadic.</p>
</sec>
</sec>
<sec id="Sec7">
<title>Natural history studies and biomarkers</title>
<p id="Par9">Until recently, clinical studies of genetic FTD have been small and single centre. However, the Genetic FTD Initiative (GENFI) started recruiting in 2012 and now encompasses 25 centres across Europe and Canada (<ext-link ext-link-type="uri" xlink:href="http://www.genfi.org.uk">http://www.genfi.org.uk</ext-link>). This is a natural history study with detailed phenotyping of both presymptomatic and symptomatic mutation carriers [<xref ref-type="bibr" rid="CR32">32</xref>]. In the US, a similar study (ARTFL/LEFFTDS) has been running for the last few years. Collaboration across natural history studies of genetic FTD across the world has started through the creation of the FTD Prevention Initiative (FPI: <ext-link ext-link-type="uri" xlink:href="http://www.genfi.org.uk/fpi.html">http://www.genfi.org.uk/fpi.html</ext-link>), aiming to share information and inform future clinical trial design.</p>
<p id="Par10">Much of the work being performed in these studies (and in other single centre investigations) over the last few years has aimed to develop validated biomarkers that robustly measure disease onset, staging and progression (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). The following sections highlight recent work in this field.<fig id="Fig2"><label>Fig. 2</label><caption><p>Schematic of fluid, imaging and cognitive biomarker profiles across the lifespan of <italic>C9orf72</italic>, <italic>MAPT</italic> and <italic>GRN</italic> mutation carriers. <italic>NfL</italic> neurofilament light chain, <italic>DTI</italic> diffusion tensor imaging, <italic>WM</italic> white matter, <italic>WMH</italic> white matter hyperintensities, <italic>GM</italic> grey matter, <italic>EF</italic> executive function, <italic>VF</italic> verbal fluency, <italic>M</italic> memory; <italic>N</italic> naming</p></caption><graphic id="MO2" xlink:href="415_2019_9363_Fig2_HTML"></graphic></fig></p>
<sec id="Sec8">
<title>Cognition</title>
<p id="Par11">Neuropsychometric measures are abnormal in presymptomatic carriers around 5 years prior to expected symptom onset [<xref ref-type="bibr" rid="CR32">32</xref>]. Whilst executive function deficits seem common across the different genetic groups, specific patterns of cognitive decline have been identified at a presymptomatic stage in <italic>MAPT</italic>, <italic>GRN</italic> and <italic>C9orf72</italic> carriers [<xref ref-type="bibr" rid="CR32">32</xref>]. A number of studies have now shown that <italic>MAPT</italic> carriers have both naming and episodic memory difficulties presymptomatically [<xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref>], consistent with early medial temporal lobe atrophy [<xref ref-type="bibr" rid="CR32">32</xref>]. As mentioned above, whilst most people develop bvFTD, some develop PPA, and one study has shown that longitudinal preclinical decline on phonology and letter fluency tasks was predictive of conversion to a nonfluent variant PPA phenotype in <italic>GRN</italic> carriers [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
</sec>
<sec id="Sec9">
<title>Neuropsychiatric and functional measures</title>
<p id="Par12">Validated measures of psychiatric symptoms or functional decline are limited in genetic FTD. The Neuropsychiatric Inventory (NPI) has been the most studied, although was not designed with FTD in mind, and does not include all relevant psychiatric symptoms that are seen in FTD [<xref ref-type="bibr" rid="CR35">35</xref>]. The Cambridge Behavioural Inventory (CBI) has been used in the GENFI study and has shown changes in proximity to symptom onset [<xref ref-type="bibr" rid="CR32">32</xref>], although as with many behavioural questionnaires there can be variability over time in FTD. More specific measures of particular symptoms such as loss of empathy (e.g. the Interpersonal Reactivity Index) or impaired self-monitoring (e.g. the Revised Self-Monitoring Scale) have not yet been well studied in genetic FTD. In terms of measuring disease severity and decline in function over time, an adaptation of the Clinical Dementia Rating scale for FTD (commonly called the FTLD-CDR) shows promise in genetic FTD [<xref ref-type="bibr" rid="CR35">35</xref>], as does the FTD Rating Scale (FRS) [<xref ref-type="bibr" rid="CR36">36</xref>], but more detailed studies of these and other novel measures are required.</p>
</sec>
<sec id="Sec10">
<title>Imaging</title>
<p id="Par13">Grey matter atrophy and hypometabolism both appear to occur at least 10 years before symptom onset in genetic FTD, whilst white matter tract abnormalities are seen earlier [<xref ref-type="bibr" rid="CR37">37</xref>]. However, there is variability both in timing and location between the different genetic groups.</p>
<sec id="Sec11">
<title>Grey matter atrophy (T1-weighted MRI)</title>
<p id="Par14">In presymptomatic <italic>MAPT</italic> carriers, atrophy is present about 15 years prior to symptom onset in the anterior and medial temporal lobes, orbitofrontal lobe and insula [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], whilst in <italic>GRN</italic> carriers, presymptomatic atrophy can be observed in frontal, parietal, and insular cortex as well as the striatum around 10 years prior to symptom onset [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Symptomatic <italic>GRN</italic> carriers commonly have a very asymmetrical pattern of brain atrophy, and this asymmetry can be observed around 5 years prior to onset [<xref ref-type="bibr" rid="CR32">32</xref>]. <italic>C9orf72</italic> mutation carriers appear to have earlier grey matter volume loss than the other two groups, before the age of 40 [<xref ref-type="bibr" rid="CR39">39</xref>], and potentially more than 25 years prior to symptom onset [<xref ref-type="bibr" rid="CR32">32</xref>]. This appears to be particularly focused on the posterior thalamus and its cortical connections [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p>
<p id="Par15">Volumetric MRI studies of genetic FTD have particularly highlighted the importance of subcortical structures in the pathogenesis of FTD, and more recent work using novel postprocessing techniques has aimed to study the subregions within these structures, e.g. there are differential patterns of atrophy within hippocampal subregions in the different genetic groups: <italic>MAPT</italic> mutation carriers had involvement of CA1-4, <italic>C9orf72</italic> expansion carriers CA4, CA1 and the dentate gyrus, and <italic>GRN</italic> mutation carriers the presubiculum and subiculum [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
<p id="Par16">There has been less focus on longitudinal investigation of grey matter atrophy; however, rates of atrophy vary between genetic groups with faster rates in <italic>GRN</italic> mutation carriers during the symptomatic period (allowing measurement over short time periods: [<xref ref-type="bibr" rid="CR41">41</xref>]) compared with the other groups. Around the time of symptom onset, there seems to be a more gradual progression of atrophy in <italic>MAPT</italic> mutation carriers but a rapid change in volume loss in <italic>GRN</italic> carriers [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
<p id="Par17">Few studies have investigated disease staging of genetic FTD. One novel machine-learning methodology combining subtyping and staging identified genetic FTD subtypes and their stages over time from structural T1-weighted imaging alone [<xref ref-type="bibr" rid="CR43">43</xref>]. Interestingly, whilst <italic>GRN</italic> and <italic>MAPT</italic> mutation carriers appeared to fall mainly into a single group, there were two distinct patterns of disease progression for <italic>C9orf72</italic> expansion carriers—it remains unclear pathophysiologically what differs between these two groups.</p>
</sec>
<sec id="Sec12">
<title>White matter hyperintensities (T2-weighted MRI)</title>
<p id="Par18">A number of studies have now shown that white matter hyperintensities (which are generally an unusual finding in FTD) are characteristic of <italic>GRN</italic> mutations [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. This is mainly in symptomatic mutation carriers (although for unclear reasons only a subset of patients), but there is also an association in presymptomatic mutation carriers with time from expected symptom onset [<xref ref-type="bibr" rid="CR45">45</xref>]. Pathological studies of these white matter hyperintensities suggest that they are not vascular but are associated with prominent white matter microglial activation and microglial dystrophy [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
</sec>
<sec id="Sec13">
<title>Hypometabolism (FDG-PET)</title>
<p id="Par19">Patterns of hypometabolism commonly mirror the pattern of grey matter atrophy in genetic FTD [<xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR51">51</xref>], with presymptomatic deficits also shown around 10 years prior to symptom onset.</p>
</sec>
<sec id="Sec14">
<title>Structural connectivity (DTI)</title>
<p id="Par20">Changes in white matter integrity are commonly measured with diffusion tensor imaging (DTI), although newer techniques such as neurite orientation dispersion and density imaging (NODDI) have recently been developed. Studies in genetic FTD suggest that changes can be observed as far back as 30 years prior to symptom onset [<xref ref-type="bibr" rid="CR52">52</xref>]. As with grey matter atrophy, there appear to be distinct patterns of early white matter involvement in the different groups: presymptomatic <italic>MAPT</italic> mutation carriers have alterations in the uncinate fasciculus and parahippocampal cingulum, while <italic>GRN</italic> mutation carriers show involvement of the anterior and posterior internal capsule [<xref ref-type="bibr" rid="CR52">52</xref>]. Presymptomatic <italic>C9orf72</italic> expansion carriers have earlier white matter tract pathology, which occurs in posterior tracts such as the posterior thalamic radiation, the posterior corona radiata and the splenium of the corpus callosum [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. A single study of NODDI suggests that it may be more sensitive than DTI for detecting early white matter change in <italic>C9orf72</italic> expansion carriers [<xref ref-type="bibr" rid="CR54">54</xref>].</p>
</sec>
<sec id="Sec15">
<title>Functional connectivity (resting-state fMRI)</title>
<p id="Par21">There have been fewer investigations of functional connectivity but small studies implicate particularly the salience network and a medial pulvinar thalamus-seeded network in presymptomatic <italic>C9orf72</italic> expansion carriers [<xref ref-type="bibr" rid="CR53">53</xref>], the default mode network in <italic>MAPT</italic> mutation carriers [<xref ref-type="bibr" rid="CR55">55</xref>] and a frontoparietal network in <italic>GRN</italic> mutation carriers [<xref ref-type="bibr" rid="CR56">56</xref>–<xref ref-type="bibr" rid="CR58">58</xref>].</p>
</sec>
<sec id="Sec16">
<title>Tau PET</title>
<p id="Par22">Studies of novel radioligands developed to bind tau protein have so far not proven to be particularly helpful in FTD, binding much more strongly to paired helical filament (PHF)-tau found mainly in Alzheimer’s disease than to other forms of tau found in the primary tauopathies. However, two particular <italic>MAPT</italic> mutations (V337M and R406W) are associated with PHF-tau and have shown strong binding with the AV1451 tracer [<xref ref-type="bibr" rid="CR59">59</xref>–<xref ref-type="bibr" rid="CR61">61</xref>]. Unfortunately, there is also off-target binding of this tracer, with binding seen in non-tau diseases such as in <italic>C9orf72</italic> expansions, where the major pathology is TDP-43 [<xref ref-type="bibr" rid="CR62">62</xref>].</p>
</sec>
</sec>
<sec id="Sec17">
<title>Blood and CSF biomarkers</title>
<p id="Par23">The fluid biomarker field in genetic FTD has yet to identify many robust measures, e.g. neither CSF nor blood assays of tau or TDP-43 are yet to yield FTD-specific markers. However, recent work has identified three markers which will play an important role in forthcoming trials: neurofilament light chain (NfL), progranulin and poly(GP) dipeptide repeat proteins (DPRs).</p>
<p id="Par24">Increased NfL levels (both in CSF and blood) reflect axonal damage and appear to be a measure of disease intensity, and predict progression and survival in genetic FTD [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Levels are highest in <italic>C9orf72</italic>-associated ALS and lowest in <italic>MAPT</italic> mutation carriers [<xref ref-type="bibr" rid="CR64">64</xref>]. Longitudinal analysis of samples seems to suggest that levels change not long prior to symptom onset in genetic FTD, increasing by three- to fourfold during conversion [<xref ref-type="bibr" rid="CR64">64</xref>]. Whilst an increase in NfL is not specific for FTD, and levels are increased in multiple neurological diseases, evidence from other diseases suggests that a decrease in levels could be a measure of successful disease modification in trials [<xref ref-type="bibr" rid="CR65">65</xref>].</p>
<p id="Par25">Low serum, plasma or CSF progranulin levels have almost perfect sensitivity and specificity for detecting pathogenic <italic>GRN</italic> mutations [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Levels are low from the earliest time period of presymptomatic genetic FTD that they have been measured [during adulthood] and are relatively stable over time [<xref ref-type="bibr" rid="CR67">67</xref>]. CSF and plasma levels are relatively poorly correlated (<italic>r</italic> = 0.54: <xref ref-type="bibr" rid="CR67">67</xref>], and little work has been done to investigate measures that affect the variability of progranulin levels. This future research is important as increasing progranulin levels back towards normal levels (and therefore theoretically restoring normal progranulin function) will be a key biomarker for disease-modifying trials in <italic>GRN</italic> carriers.</p>
<p id="Par26">Increased poly(GP) levels have been identified in the CSF of <italic>C9orf72</italic> expansion carriers both presymptomatically and symptomatically [<xref ref-type="bibr" rid="CR68">68</xref>–<xref ref-type="bibr" rid="CR70">70</xref>]. One study found slightly lower levels in presymptomatic expansion carriers compared with symptomatic carriers [<xref ref-type="bibr" rid="CR70">70</xref>] but that has not been seen consistently. More work needs to be performed to understand variability further, but like NfL, decreasing levels of CSF poly(GP) post-treatment may be suggestive of disease modification in future trials.</p>
<p id="Par27">A particular focus of biomarker research in genetic FTD is the development of markers of neuroinflammation. CHIT1 and YKL-40 are microglial markers that appear to be raised in symptomatic genetic FTD [<xref ref-type="bibr" rid="CR71">71</xref>] with little evidence for a change during the presymptomatic period so far. In a small study, CSF sTREM2 levels were raised in <italic>GRN</italic> mutation carriers but not the other genetic groups [<xref ref-type="bibr" rid="CR72">72</xref>].</p>
</sec>
</sec>
<sec id="Sec18">
<title>Clinical practice (Fig. <xref ref-type="fig" rid="Fig3">3</xref>)</title>
<sec id="Sec19">
<title>Symptomatic genetic testing</title>
<p id="Par28">Testing in symptomatic patients with dementia has changed in recent years. Next-generation sequencing (NGS) panels are now available to test multiple genes at the same time—these have identified mutations causative of FTD pathology not just in those with an FTD clinical syndrome [<xref ref-type="bibr" rid="CR73">73</xref>]. Issues that remain to be solved in clinical genetic testing include: how to decide the pathogenicity of certain variants (of which more are now found because of NGS); the exact length at which <italic>C9orf72</italic> expansions become pathogenic (as intermediate length expansions are not clearly causative of disease [<xref ref-type="bibr" rid="CR74">74</xref>]); and what to do when no mutation is found in a family with autosomal dominant FTD. In terms of this latter problem, many available NGS panels do not include the more recently discovered genes such as <italic>TBK1</italic> and we have identified mutations in these genes by exome sequencing in those with negative NGS and C9orf72 sequencing [<xref ref-type="bibr" rid="CR30">30</xref>]. However there are still a small number of families with a strong family history of FTD without a known genetic mutation. We offer genetic testing in our clinic to all those with bvFTD, even in the absence of a family history, as mutations have been found in around 10% of apparently sporadic cases of FTD [<xref ref-type="bibr" rid="CR75">75</xref>]. In the other FTD clinical phenotypes, where the risk is lower of a genetic cause, we offer testing on an individual basis, mainly in those with a strong family history, but the identification of a PPA syndrome not fitting criteria for one of the three described subtypes is a red flag for consideration of testing (with the expectation of potentially finding a <italic>GRN</italic> mutation) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR76">76</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><p>Genetic testing, counselling and support through the timecourse of genetic FTD. There is commonly a period in proximity to symptom onset of FTD where subtle symptoms may be present but diagnostic criteria have not yet been met—this requires careful assessment and discussion</p></caption><graphic id="MO3" xlink:href="415_2019_9363_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="Sec20">
<title>Presymptomatic genetic testing</title>
<p id="Par29">Once a causal mutation has been established in a symptomatic relative, the option of predictive genetic testing can be raised with at-risk family members. While potential treatments for FTD are still lacking, appropriate clinical care for presymptomatic populations is integral. The genetic counselling and support systems in place lag far behind those seen in other neurodegenerative disorders. Whilst in practice the HD predictive genetic testing protocol is currently used as the gold standard [<xref ref-type="bibr" rid="CR77">77</xref>], there are a number of key distinctions between HD and FTD which mean that the HD protocol may not be appropriate for the FTD population [<xref ref-type="bibr" rid="CR78">78</xref>], including age-related penetrance, unpredictable age at onset of symptoms, and phenotypic heterogeneity. Similarly, access, experiences and attitudes towards predictive testing can vary depending on location [<xref ref-type="bibr" rid="CR79">79</xref>], and future development of an FTD-specific protocol may be more suitable.</p>
<p id="Par30">The HD predictive guidelines stress the importance of psychological evaluation in presymptomatic carriers, with others suggesting that psychological assessment is a necessary process for identifying an individual’s risk of experiencing an adverse psychological reaction to presymptomatic testing [<xref ref-type="bibr" rid="CR80">80</xref>]. There remain a large proportion of individuals who live at-risk of FTD who decide against predictive testing—probably about 70–80% of this population [<xref ref-type="bibr" rid="CR32">32</xref>]. These individuals receive little or no support as many will not have even been through genetic counselling, and little work has been done to identify their psychological needs. Initial research does suggest that rates of depression and mood disorders are higher even in non-carriers within FTD families [<xref ref-type="bibr" rid="CR81">81</xref>]. One method of helping such individuals is the provision of specific support groups aimed at providing peer support and information about the at-risk period—the familial FTD support group in the UK is one such example (<ext-link ext-link-type="uri" xlink:href="http://www.raredementiasupport.org/fftd/">http://www.raredementiasupport.org/fftd/</ext-link>). Specific interventions at an appropriate time such as cognitive behaviour therapy or mindfulness have yet to be trialled.</p>
</sec>
</sec>
<sec id="Sec21">
<title>Clinical trials and emerging therapies</title>
<p id="Par31">There are currently no disease-modifying therapies for genetic FTD but trials are now underway or planned in each of the three main genetic FTD groups. Antisense oligonucleotide therapy shows promise for both C9orf72 expansions [<xref ref-type="bibr" rid="CR82">82</xref>] and <italic>MAPT</italic> mutations [<xref ref-type="bibr" rid="CR83">83</xref>], whilst AAV gene therapy is a potential avenue for disease modification in <italic>GRN</italic> carriers [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>], although one study in a mouse model showed evidence of T cell-mediated toxicity [<xref ref-type="bibr" rid="CR85">85</xref>]. Small molecule therapies and tau monoclonal antibodies are also being developed for tauopathies (with a potential for use in <italic>MAPT</italic> mutations) [<xref ref-type="bibr" rid="CR86">86</xref>], and other options for <italic>GRN</italic> mutations include modification of proteins such as sortilin and HDAC that lead to increased <italic>GRN</italic> levels [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>].</p>
</sec>
<sec id="Sec22">
<title>Summary</title>
<p id="Par32">Much has been learnt about genetic FTD in the last decade, with the majority of autosomal dominant FTD now accounted for. The development of collaborative international multicentre natural history studies in GENFI and ARTFL/LEFFTDS has brought together researchers and families, and has helped to set the background for clinical trials that are now getting started and being planned. An associated support network for those living at-risk of genetic FTD is important and there is work to be done in improving this; but with the advent of specific gene-targeted therapeutics, there is hope in the community for the future outlook.</p>
</sec>
</body>
<back>
<notes notes-type="ethics">
<title>Compliance with ethical standards</title>
<notes notes-type="COI-statement">
<title>Conflicts of interest</title>
<p id="Par33">We have no conflicts of interest.</p>
</notes>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coyle-Gilchrist</surname>
<given-names>IT</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vázquez Rodríquez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wehmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wilcox</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lansdall</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Wiggins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brayne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes</article-title>
<source/>Neurology
          <year>2016</year>
<volume>86</volume>
<issue>18</issue>
<fpage>1736</fpage>
<lpage>1743</lpage>
<pub-id pub-id-type="pmid">27037234</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rascovsky</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mendez</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Neuhaus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Seelaar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Onyike</surname>
<given-names>CU</given-names>
</name>
<name>
<surname>Hillis</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Kertesz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Rankin</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Gorno-Tempini</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Prioleau-Latham</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kipps</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Lillo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Piguet</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Galasko</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Salmon</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Mesulam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Diehl-Schmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Deramecourt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lebert</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pijnenburg</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Manes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Grafman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cappa</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</article-title>
<source/>Brain
          <year>2011</year>
<volume>134</volume>
<issue>Pt 9</issue>
<fpage>2456</fpage>
<lpage>2477</lpage>
<pub-id pub-id-type="pmid">21810890</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorno-Tempini</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Hillis</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kertesz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mendez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cappa</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Ogar</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Manes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dronkers</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Vandenberghe</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rascovsky</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Mesulam</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Classification of primary progressive aphasia and its variants</article-title>
<source/>Neurology
          <year>2011</year>
<volume>76</volume>
<issue>11</issue>
<fpage>1006</fpage>
<lpage>1014</lpage>
<pub-id pub-id-type="pmid">21325651</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strong</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Abrahams</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Woolley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mclaughlin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Snowden</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mioshi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Roberts-South</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Benatar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>HortobáGyi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Silani</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ince</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Amyotrophic lateral sclerosis—frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria</article-title>
<source/>Amyotroph Later Scler Frontotempor Degener
          <year>2017</year>
<volume>18</volume>
<issue>3–4</issue>
<fpage>153</fpage>
<lpage>174</lpage>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Litvan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Bak</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hallett</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Kertesz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Reich</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Tolosa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tröster</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Vidailhet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Criteria for the diagnosis of corticobasal degeneration</article-title>
<source/>Neurology
          <year>2013</year>
<volume>80</volume>
<issue>5</issue>
<fpage>496</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="pmid">23359374</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Höglinger</surname>
<given-names>GU</given-names>
</name>
<name>
<surname>Respondek</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stamelou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kurz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Mollenhauer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Arzberger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Englund</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gelpi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Meissner</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Pantelyat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rajput</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Troakes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Bordelon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Compta</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Corvol</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Colosimo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Dodel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kassubek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krismer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lorenzl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Nestor</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Oertel</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Poewe</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rabinovici</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Schellenberg</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Seppi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van Eimeren</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wenning</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Golbe</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Litvan</surname>
<given-names>I</given-names>
</name>
<collab>Movement Disorder Society-endorsed PSPStudy Group</collab>
</person-group>
<article-title>Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria</article-title>
<source/>Mov Disord
          <year>2017</year>
<volume>32</volume>
<issue>6</issue>
<fpage>853</fpage>
<lpage>864</lpage>
<pub-id pub-id-type="pmid">28467028</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beck</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Isaacs</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Goodall</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Warrington</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Revesz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Al-Sarraj</surname>
<given-names>S</given-names>
</name>
<name>
<surname>King</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scahill</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Collinge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series</article-title>
<source/>Brain
          <year>2008</year>
<volume>131</volume>
<issue>Pt 3</issue>
<fpage>706</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="pmid">18234697</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Guerreiro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vandrovcova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Uphill</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reiman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Isaacs</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Authier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IRA</given-names>
</name>
</person-group>
<article-title>The heritability and genetics of frontotemporal lobar degeneration</article-title>
<source/>Neurology
          <year>2009</year>
<volume>73</volume>
<fpage>1451</fpage>
<lpage>1456</lpage>
<pub-id pub-id-type="pmid">19884572</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Falcone</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Chen-Plotkin</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>SX</given-names>
</name>
<name>
<surname>Van Deerlin</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Development and validation of pedigree classification criteria for frontotemporal lobar degeneration</article-title>
<source/>JAMA Neurol
          <year>2013</year>
<volume>70</volume>
<issue>11</issue>
<fpage>1411</fpage>
<lpage>1417</lpage>
<pub-id pub-id-type="pmid">24081456</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neuhaus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lomen-Hoerth</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wilhelmsen</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Comparison of family histories in FTLD subtypes and related tauopathies</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<issue>11</issue>
<fpage>1817</fpage>
<lpage>1819</lpage>
<pub-id pub-id-type="pmid">16344531</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Po</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>FV</given-names>
</name>
<name>
<surname>Gracia</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bartley</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Burrell</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Heritability in frontotemporal dementia: more missing pieces</article-title>
<source/>J Neurol
          <year>2014</year>
<volume>261</volume>
<issue>11</issue>
<fpage>2170</fpage>
<lpage>2177</lpage>
<pub-id pub-id-type="pmid">25156163</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahoney</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lashley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shakespeare</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yeatman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Warrington</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Collinge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Revesz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features</article-title>
<source/>Brain
          <year>2012</year>
<volume>135</volume>
<issue>Pt 3</issue>
<fpage>736</fpage>
<lpage>750</lpage>
<pub-id pub-id-type="pmid">22366791</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snowden</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Rollinson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Stopford</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gerhard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>DuPlessis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Neary</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Pickering-Brown</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72mutations</article-title>
<source/>Brain
          <year>2012</year>
<volume>135</volume>
<issue>Pt 3</issue>
<fpage>693</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="pmid">22300873</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bonvicini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tremolizzo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Papetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Archetti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Turla</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alberici</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agosti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Premi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Appollonio</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rainero</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ferrarese</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gennarelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Founder effect and estimation of the age of the progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration</article-title>
<source/>Neurobiol Aging
          <year>2011</year>
<volume>32</volume>
<issue>3</issue>
<fpage>555.e1</fpage>
<lpage>555.e8</lpage>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barandiaran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Estanga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Indakoetxea</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alzualde</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Balluerka</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Martí Massó</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>de López Munain</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Neuropsychological features of asymptomatic c.709–1G &gt; A progranulin mutation carriers</article-title>
<source/>J Int Neuropsychol Soc
          <year>2012</year>
<volume>18</volume>
<issue>6</issue>
<fpage>1086</fpage>
<lpage>1090</lpage>
<pub-id pub-id-type="pmid">23158232</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redaelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maderna</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Piccoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Caroppo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cacciatore</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Spinello</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grisoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sozzi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Salmaggi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Giaccone</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (TAR DNA-binding protein 43 inclusions) in missense progranulin mutation Cys139Arg</article-title>
<source/>Brain Pathol
          <year>2018</year>
<volume>28</volume>
<issue>1</issue>
<fpage>72</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">27997711</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Majo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Topp</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Gkazi</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Baas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ten Asbroek</surname>
<given-names>ALMA</given-names>
</name>
<name>
<surname>Kenna</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Ticozzi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Redondo</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Esteban-Pérez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tiloca</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Verde</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Duga</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hardiman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>de Belleroche</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gellera</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ratti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Chalabi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Silani</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Landers</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function</article-title>
<source/>Neurobiol Aging
          <year>2018</year>
<volume>71</volume>
<fpage>266.e1</fpage>
<lpage>266.e10</lpage>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Floris</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Borghero</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cannas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Di Stefano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Murru</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Corongiu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cuccu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tranquilli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cherchi</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Loi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marrosu</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Chio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marrosu</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations</article-title>
<source/>J Neurol
          <year>2015</year>
<volume>262</volume>
<fpage>375</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="pmid">25408367</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gass</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adamson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Crook</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Melquist</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kuntz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Josephs</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pickering-Brown</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Graff-Radford</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Uitti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beach</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mesulam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>White</surname>
<given-names>CL</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Woodruff</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Caselli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hsiung</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hutton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration</article-title>
<source/>Hum Mol Genet
          <year>2006</year>
<volume>15</volume>
<issue>20</issue>
<fpage>2988</fpage>
<lpage>3001</lpage>
<pub-id pub-id-type="pmid">16950801</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Arthur</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Tienari</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chiò</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Age-related penetrance of the C9orf72 repeat expansion</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>2116</fpage>
<pub-id pub-id-type="pmid">28522837</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicholson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>What we know about TMEM106B in neurodegeneration</article-title>
<source/>Acta Neuropathol
          <year>2016</year>
<volume>132</volume>
<issue>5</issue>
<fpage>639</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="pmid">27543298</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pottier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Perkerson</surname>
<given-names>RB</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Baker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Serie</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Binetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>López de Munain</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zulaica</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hannequin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sánchez-Valle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Antonell</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lladó</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Finch</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Finger</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Lippa</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Huey</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heutink</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Synofzik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wilke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rissman</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Slawek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sitek</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Johannsen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>van Blitterswijk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>DeJesus-Hernandez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Christopher</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Bieniek</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Evers</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rollinson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fumagalli</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Momeni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Frangipane</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Maletta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Anfossi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Petrucelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>van Rooij</surname>
<given-names>JGJ</given-names>
</name>
<name>
<surname>Seelaar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Caselli</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Reiman</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Noel Sabbagh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kjolby</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nykjaer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karydas</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Grinberg</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Grafman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oblak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mesulam</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Geula</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Piguet</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Ertekin-Taner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Nacmias</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Piaceri</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bagnoli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gearing</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beach</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rogaeva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vonsattel</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Honig</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Kofler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bruni</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Snowden</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pickering-Brown</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Diehl-Schmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Winkelmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Öijerstedt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Troakes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Al-Sarraj</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cruchaga</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>White</surname>
<given-names>CL</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Ghetti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Murell</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IRA</given-names>
</name>
<name>
<surname>Hsiung</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>ZK</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van Deerlin</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Graff-Radford</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Biernacka</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study</article-title>
<source/>Lancet Neurol
          <year>2018</year>
<volume>17</volume>
<issue>6</issue>
<fpage>548</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="pmid">29724592</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Keith</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Surace</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Grinberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dupont</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McGoldrick</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weichert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McKeever</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McCorkindale</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Manzoni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Graff-Radford</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>van Rooij</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pijnenburg</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>van der Zee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Van Broeckhoven</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van Deerlin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oijerstedt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pickering-Brown</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rollinson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Dobson-Stone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Piguet</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Binetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nacmias</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bruni</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rainero</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rubino</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Clarimon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lleo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pastor</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Diez-Fairen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Deramecourt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lebouvier</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perneczky</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Diehl-Schmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grafman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huey</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Mayeux</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Momeni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zinman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rogaeva</surname>
<given-names>E</given-names>
</name>
<collab>International FTDGC</collab>
</person-group>
<article-title>A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers</article-title>
<source/>Brain
          <year>2018</year>
<volume>141</volume>
<fpage>2895</fpage>
<lpage>2907</lpage>
<pub-id pub-id-type="pmid">30252044</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fournier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barbier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Camuzat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anquetil</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lattante</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Clot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cazeneuve</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rinaldi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Couratier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Deramecourt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sabatelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Belliard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vercelletto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Forlani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jornea</surname>
<given-names>L</given-names>
</name>
<collab>French Clinical and Genetic Research Network on FTLD/FTLD-ALS; PREVDEMALS and FTLD-Exome Study Groups</collab>
<name>
<surname>Leguern</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers</article-title>
<source/>Neurobiol Aging
          <year>2019</year>
<volume>74</volume>
<fpage>234.e1</fpage>
<lpage>234.e8</lpage>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koriath</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lashley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Druyeh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dimitriadis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Denning</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Collinge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-β copathology</article-title>
<source/>Alzheimers Dement (Amst)
          <year>2019</year>
<volume>11</volume>
<fpage>277</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="pmid">30949567</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Crutch</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Warrington</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Progranulin-associated primary progressive aphasia: a distinct phenotype?</article-title>
<source/>Neuropsychologia
          <year>2010</year>
<volume>48</volume>
<issue>1</issue>
<fpage>288</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="pmid">19766663</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devenney</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Halliday</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Piguet</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kiernan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members</article-title>
<source/>Neurology
          <year>2018</year>
<volume>91</volume>
<fpage>e1498</fpage>
<lpage>e1507</lpage>
<pub-id pub-id-type="pmid">30258023</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ducharme</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bajestan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Voon</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Psychiatric presentations of C9orf72 mutation: what are the diagnostic implications for clinicians?</article-title>
<source/>J Neuropsychiatry Clin Neurosci
          <year>2017</year>
<volume>29</volume>
<fpage>195</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="pmid">28238272</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourinaris</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>C9orf72 and its relevance in Parkinsonism and movement disorders: a comprehensive review of the literature</article-title>
<source/>Mov Disord Clin Pract
          <year>2018</year>
<volume>5</volume>
<issue>6</issue>
<fpage>575</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="pmid">30637277</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koriath</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brotherhood</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Woollacott</surname>
<given-names>IO</given-names>
</name>
<name>
<surname>Norsworthy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Simón-Sánchez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blauwendraat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Crutch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Revesz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lashley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>The clinical, neuroanatomical, and neuropathologic phenotype of <italic>TBK1</italic>-associated frontotemporal dementia: a longitudinal case report</article-title>
<source/>Alzheimers Dement (Amst)
          <year>2016</year>
<volume>6</volume>
<fpage>75</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">28229125</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caroppo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Camuzat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Septenville</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Couratier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lacomblez</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Auriacombe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Flabeau</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Jornéa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blanc</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sellal</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cretin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Meininger</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fleury</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Couarch</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Semantic and nonfluent aphasic variants, secondarily associated with amyotrophic lateral sclerosis, are predominant frontotemporal lobar degeneration phenotypes in TBK1 carriers</article-title>
<source/>Alzheimers Dement (Amst)
          <year>2015</year>
<volume>1</volume>
<issue>4</issue>
<fpage>481</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="pmid">27239526</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Nicholas</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jiskoot</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rombouts</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Clegg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Espak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>De Vita</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Keren</surname>
<given-names>R</given-names>
</name>
<name>
<surname>MacIntosh</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Rogaeva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tang-Wai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tiraboschi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Redaelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Prioni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grisoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Arighi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fumagalli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Coyle-Gilchrist</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fallstrom</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jelic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Stahlbom</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thonberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lilius</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frisoni</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Pievani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Finger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nacmias</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Polito</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Binetti</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis</article-title>
<source/>Lancet Neurol
          <year>2015</year>
<volume>14</volume>
<fpage>253</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="pmid">25662776</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiskoot</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Panman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>van Asseldonk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Franzen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meeter</surname>
<given-names>LHH</given-names>
</name>
<name>
<surname>Donker Kaat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van der Ende</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>EGP</given-names>
</name>
<name>
<surname>Timman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>van den Berg</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Papma</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia</article-title>
<source/>J Neurol
          <year>2018</year>
<volume>265</volume>
<fpage>1381</fpage>
<lpage>1392</lpage>
<pub-id pub-id-type="pmid">29627938</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheran</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Manoochehri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cines</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fallon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heidebrink</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huey</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Cognitive indicators of preclinical behavioral variant frontotemporal dementia in MAPT carriers</article-title>
<source/>J Int Neuropsychol Soc
          <year>2019</year>
<volume>25</volume>
<issue>2</issue>
<fpage>184</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="pmid">30458895</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Premi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gualeni</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cosseddu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gasparotti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Looking for measures of disease severity in the frontotemporal dementia continuum</article-title>
<source/>J Alzheimers Dis
          <year>2016</year>
<volume>52</volume>
<issue>4</issue>
<fpage>1227</fpage>
<lpage>1235</lpage>
<pub-id pub-id-type="pmid">27104906</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mioshi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hornberger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Clinical staging and disease progression in frontotemporal dementia</article-title>
<source/>Neurology
          <year>2010</year>
<volume>74</volume>
<issue>20</issue>
<fpage>1591</fpage>
<lpage>1597</lpage>
<pub-id pub-id-type="pmid">20479357</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meeter</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Kaat</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Imaging and fluid biomarkers in frontotemporal dementia</article-title>
<source/>Nat Rev Neurol
          <year>2017</year>
<volume>13</volume>
<fpage>406</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="pmid">28621768</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cash</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Frisoni</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Finger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>de Mendonca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<collab>Genetic Ftd Initiative G</collab>
</person-group>
<article-title>Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study</article-title>
<source/>Neurobiol Aging
          <year>2018</year>
<volume>62</volume>
<fpage>191</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">29172163</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertrand</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rinaldi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Houot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sayah</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Camuzat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fontanella</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Routier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Couratier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Habert</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Hannequin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martinaud</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Caroppo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Durrleman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Colliot</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
<collab>Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (PREV-DEMALS) Study Group</collab>
</person-group>
<article-title>Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years</article-title>
<source/>JAMA Neurol
          <year>2018</year>
<volume>75</volume>
<issue>2</issue>
<fpage>236</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">29197216</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iglesias</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Scelsi</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Modat</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Altmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Hippocampal subfield volumetry: differential pattern of atrophy in different forms of genetic frontotemporal dementia</article-title>
<source/>J Alzheimers Dis
          <year>2018</year>
<volume>64</volume>
<fpage>497</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="pmid">29889066</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sha</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mitic</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Karydas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koestler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Corbetta-Rastelli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fleischmann</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Powers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fitch</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Martens</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Shamloo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Farese</surname>
<given-names>RV</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Pearlman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from <italic>GRN</italic> gene mutations</article-title>
<source/>Alzheimers Dement (N Y)
          <year>2017</year>
<volume>3</volume>
<issue>4</issue>
<fpage>507</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="pmid">29124108</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiskoot</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Panman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Meeter</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>EGP</given-names>
</name>
<name>
<surname>Donker Kaat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Franzen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van der Ende</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rombouts</surname>
<given-names>SARB</given-names>
</name>
<name>
<surname>Papma</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia</article-title>
<source/>Brain
          <year>2019</year>
<volume>142</volume>
<issue>1</issue>
<fpage>193</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="pmid">30508042</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Marinescu</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Oxtoby</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Firth</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Frisoni</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Finger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>de Mendonça</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Crutch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>DC</given-names>
</name>
<collab>Genetic FTD Initiative (GENFI); Alzheimer’s Disease Neuroimaging Initiative (ADNI)</collab>
</person-group>
<article-title>Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference</article-title>
<source/>Nat Commun
          <year>2018</year>
<volume>9</volume>
<issue>1</issue>
<fpage>4273</fpage>
<pub-id pub-id-type="pmid">30323170</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caroppo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Camuzat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Clot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Naccache</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lamari</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Septenville</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Belliard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hannequin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Colliot</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin</article-title>
<source/>JAMA Neurol
          <year>2014</year>
<volume>71</volume>
<issue>12</issue>
<fpage>1562</fpage>
<lpage>1566</lpage>
<pub-id pub-id-type="pmid">25317628</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudre</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Woollacott</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Frisoni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Finger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>de Mendonça</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<collab>Genetic FTD Initiative, GENFI</collab>
</person-group>
<article-title>White matter hyperintensities are seen only in <italic>GRN</italic> mutation carriers in the GENFI cohort</article-title>
<source/>Neuroimage Clin
          <year>2017</year>
<volume>15</volume>
<fpage>171</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="pmid">28529873</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woollacott</surname>
<given-names>IOC</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sudre</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Ridha</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Strand</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Courtney</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Revesz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lashley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia</article-title>
<source/>Neurocase
          <year>2018</year>
<volume>24</volume>
<issue>3</issue>
<fpage>166</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="pmid">30112957</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deters</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Risacher</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Farlow</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Unverzagt</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Kareken</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hutchins</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Yoder</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Murrell</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Spina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Epperson</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Saykin</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ghetti</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Cerebral hypometabolism and grey matter density in MAPT intron 10+ 3 mutation carriers</article-title>
<source/>Am J Neurodegener Dis
          <year>2014</year>
<volume>3</volume>
<fpage>103</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">25628962</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caroppo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Habert</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Durrleman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Funkiewiez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perlbarg</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bertin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gaubert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Routier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hannequin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deramecourt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rivaud-Pechoux</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vercelletto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Edouart</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Valabregue</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lejeune</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Didic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Corvol</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Benali</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lehericy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Colliot</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Psg</surname>
<given-names>Predict</given-names>
</name>
</person-group>
<article-title>Lateral temporal lobe: an early imaging marker of the presymptomatic GRN disease?</article-title>
<source/>J Alzheimers Dis
          <year>2015</year>
<volume>47</volume>
<fpage>751</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="pmid">26401709</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacova</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hsiung</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Tawankanjanachot</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dinelle</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sengdy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bouchard-Kerr</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sossi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Stoessl</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
</person-group>
<article-title>Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers</article-title>
<source/>Neurology
          <year>2013</year>
<volume>81</volume>
<fpage>1322</fpage>
<lpage>1331</lpage>
<pub-id pub-id-type="pmid">24005336</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diehl-Schmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Licata</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goldhardt</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Förstl</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yakushew</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anderl-Straub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Beer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ludolph</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Landwehrmeyer</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Danek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fliessbach</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Spottke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fassbender</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lyros</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Prudlo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Edbauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schroeter</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Drzezga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kornhuber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lauer</surname>
<given-names>M</given-names>
</name>
<collab>FTLDc Study Group</collab>
<name>
<surname>Grimmer</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations</article-title>
<source/>Transl Psychiatry
          <year>2019</year>
<volume>9</volume>
<issue>1</issue>
<fpage>54</fpage>
<pub-id pub-id-type="pmid">30705258</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cistaro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Montuschi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moglia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Canosa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Restagno</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brunetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Carrara</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fania</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lopiano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Valentini</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Chio</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The metabolic signature of C9ORF72-related ALS: fDG PET comparison with nonmutated patients</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2014</year>
<volume>41</volume>
<fpage>844</fpage>
<lpage>852</lpage>
<pub-id pub-id-type="pmid">24445987</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiskoot</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicholas</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Modat</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rombouts</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>EGP</given-names>
</name>
<name>
<surname>Meeter</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Panman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van der Ende</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Donker Kaat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pijnenburg</surname>
<given-names>YAL</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Frisoni</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Finger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>de Mendonca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S</given-names>
</name>
<collab>Genetic Frontotemporal dementia I</collab>
<name>
<surname>Papma</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: a cross-sectional diffusion tensor imaging study</article-title>
<source/>Ann Clin Transl Neurol
          <year>2018</year>
<volume>5</volume>
<fpage>1025</fpage>
<lpage>1036</lpage>
<pub-id pub-id-type="pmid">30250860</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Sias</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mandelli</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Khazenzon</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Vidovszky</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Zanto</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Karydas</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Pribadi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dokuru</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gorno-Tempini</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>WW</given-names>
</name>
</person-group>
<article-title>Network degeneration and dysfunction in presymptomatic <italic>C9ORF72</italic> expansion carriers</article-title>
<source/>Neuroimage Clin
          <year>2016</year>
<volume>14</volume>
<fpage>286</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="pmid">28337409</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Durrleman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Routier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rinaldi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Houot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Couratier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hannequin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Colliot</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>A</given-names>
</name>
<collab>Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (PREV-DEMALS) Study Group</collab>
</person-group>
<article-title>Neurite density is reduced in the presymptomatic phase of <italic>C9orf72</italic> disease</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2018</year>
<volume>90</volume>
<issue>4</issue>
<fpage>387</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="pmid">30355607</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Avula</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tosakulwong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weigand</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Senjem</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Vemuri</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Gunter</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>ZK</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD</article-title>
<source/>Neurology
          <year>2011</year>
<volume>77</volume>
<issue>9</issue>
<fpage>866</fpage>
<lpage>874</lpage>
<pub-id pub-id-type="pmid">21849646</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Premi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cauda</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gasparotti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Diano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Archetti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Multimodal FMRI resting-state functional connectivity in granulin mutations: the case of fronto-parietal dementia</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>9</issue>
<fpage>e106500</fpage>
<pub-id pub-id-type="pmid">25188321</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pievani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paternicò</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Binetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Orlandini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cobelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magnaldi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Frisoni</surname>
<given-names>GB</given-names>
</name>
</person-group>
<article-title>Pattern of structural and functional brain abnormalities in asymptomatic granulin mutation carriers</article-title>
<source/>Alzheimers Dement
          <year>2014</year>
<volume>10</volume>
<issue>5 Suppl</issue>
<fpage>S354</fpage>
<lpage>S363</lpage>
<pub-id pub-id-type="pmid">24418059</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dopper</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Rombouts</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Jiskoot</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>den Heijer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>de Graaf</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>de Koning</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hammerschlag</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Seelaar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Veer</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>van Buchem</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rizzu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia</article-title>
<source/>Neurology
          <year>2014</year>
<volume>83</volume>
<issue>2</issue>
<fpage>e19</fpage>
<lpage>e26</lpage>
<pub-id pub-id-type="pmid">25002573</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schonhaut</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Ossenkoppele</surname>
<given-names>R</given-names>
</name>
<name>
<surname>O’Neil</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Lazaris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Jagust</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Rabinovici</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Frontotemporal dementia with the V337M MAPT mutation: tau-PET and pathology correlations</article-title>
<source/>Neurology
          <year>2017</year>
<volume>88</volume>
<fpage>758</fpage>
<lpage>766</lpage>
<pub-id pub-id-type="pmid">28130473</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Graff-Radford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Syrjanen</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Senjem</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Dheel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kantarci</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Lowe</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
</person-group>
<article-title>In vivo <sub>18</sub>F-AV-1451 tau PET signal in <italic>MAPT</italic> mutation carriers varies by expected tau isoforms</article-title>
<source/>Neurology
          <year>2018</year>
<volume>90</volume>
<fpage>947</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="pmid">29695599</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schöll</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ohlsson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Honer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Englund</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers</article-title>
<source/>Brain
          <year>2016</year>
<volume>139</volume>
<fpage>2372</fpage>
<lpage>2379</lpage>
<pub-id pub-id-type="pmid">27357347</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bevan-Jones</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Cope</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Passamonti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Coles</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Aigbirhio</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>[<sub>18</sub>F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion</article-title>
<source/>Ann Clin Transl Neurol
          <year>2018</year>
<volume>5</volume>
<fpage>1292</fpage>
<lpage>1296</lpage>
<pub-id pub-id-type="pmid">30349864</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Woollacott</surname>
<given-names>IO</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Brotherhood</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fellows</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Toombs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Druyeh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nicholas</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Norgren</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Andreasson</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia</article-title>
<source/>Neurology
          <year>2016</year>
<volume>87</volume>
<fpage>1329</fpage>
<lpage>1336</lpage>
<pub-id pub-id-type="pmid">27581216</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meeter</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Jiskoot</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Sanchez-Valle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pijnenburg</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vandenberghe</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ber</surname>
<given-names>IL</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Papma</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rombouts</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Balasa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Öijerstedt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jelic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Jorge Cardoso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ourselin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fenoglio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Lamari</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Barro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kuhle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Teunissen</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Neurofilament light chain: a biomarker for genetic frontotemporal dementia</article-title>
<source/>Ann Clin Transl Neurol
          <year>2016</year>
<volume>3</volume>
<issue>8</issue>
<fpage>623</fpage>
<lpage>636</lpage>
<pub-id pub-id-type="pmid">27606344</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winter</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Guenther</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ludolph</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Hermann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wurster</surname>
<given-names>CD</given-names>
</name>
</person-group>
<article-title>Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2019</year>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fumagalli</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Fenoglio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cioffi</surname>
<given-names>SMG</given-names>
</name>
<name>
<surname>Arighi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Serpente</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tagliavini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Masellis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meeter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>de Mendonça</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
<collab>Genetic FTD Initiative (GENFI)</collab>
</person-group>
<article-title>Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study</article-title>
<source/>Neurobiol Aging
          <year>2018</year>
<volume>62</volume>
<fpage>245.e9</fpage>
<lpage>245.e12</lpage>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meeter</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Patzke</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Loewen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Pijnenburg</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers</article-title>
<source/>Dement Geriatr Cogn Dis Extra
          <year>2016</year>
<volume>6</volume>
<issue>2</issue>
<fpage>330</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="pmid">27703466</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gendron</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Chew</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stankowski</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Prudencio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carlomagno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Daughrity</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Jansen-West</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Perkerson</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>O’Raw</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pregent</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Belzil</surname>
<given-names>V</given-names>
</name>
<name>
<surname>van Blitterswijk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tabassian</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Castanedes-Casey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rousseau</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rush</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Pedraza</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Caputo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Desaro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Palmucci</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heckman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Wiggs</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tierney</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Farren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lacomis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ladha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>McCluskey</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Elman</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Toledo</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Tiloca</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Solca</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Prelle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wuu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jockel-Balsarotti</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rigo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ambrose</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Datta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Raitcheva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Antognetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McCampbell</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Bowser</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Ratti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Disney</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Benatar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silani</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Floeter</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Rothstein</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Boylan</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Petrucelli</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Poly(GP) proteins are a useful pharmacodynamic marker for <italic>C9ORF72</italic>-associated amyotrophic lateral sclerosis</article-title>
<source/>Sci Transl Med
          <year>2017</year>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lehmer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oeckl</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weishaupt</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Diehl-Schmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schroeter</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kornhuber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fassbender</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Landwehrmeyer</surname>
<given-names>B</given-names>
</name>
<collab>German Consortium for Frontotemporal Lobar Degeneration</collab>
<name>
<surname>Schludi</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Arzberger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Flatley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Feederle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Steinacker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weydt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ludolph</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Edbauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Poly-GP in cerebrospinal fluid links <italic>C9orf72</italic>-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD</article-title>
<source/>EMBO Mol Med
          <year>2017</year>
<volume>9</volume>
<issue>7</issue>
<fpage>859</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="pmid">28408402</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meeter</surname>
<given-names>LHH</given-names>
</name>
<name>
<surname>Gendron</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Sias</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Jiskoot</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Donker Kaat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Papma</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Panman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>van der Ende</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Franzen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Sanchez-Valle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pijnenburg</surname>
<given-names>YAL</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Del Campo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Teunissen</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Karydas</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Öijerstedt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Binetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Bocchetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Petrucelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Poly(GP), neurofilament and grey matter deficits in <italic>C9orf72</italic> expansion carriers</article-title>
<source/>Ann Clin Transl Neurol
          <year>2018</year>
<volume>5</volume>
<issue>5</issue>
<fpage>583</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="pmid">29761121</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oeckl</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weydt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Steinacker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Anderl-Straub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nordin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Diehl-Schmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kornhuber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Danek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fassbender</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fliessbach</surname>
<given-names>K</given-names>
</name>
<collab>German Consortium for Frontotemporal Lobar Degeneration</collab>
<name>
<surname>Jahn</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Knehr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Prudlo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thal</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Yilmazer-Hanke</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weishaupt</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Ludolph</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2019</year>
<volume>90</volume>
<issue>1</issue>
<fpage>4</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">30224549</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woollacott</surname>
<given-names>IOC</given-names>
</name>
<name>
<surname>Nicholas</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Heslegrave</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Foiani</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Paterson</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Keshavan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup</article-title>
<source/>Alzheimers Res Ther
          <year>2018</year>
<volume>10</volume>
<issue>1</issue>
<fpage>79</fpage>
<pub-id pub-id-type="pmid">30111356</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koriath</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Adamson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Druyeh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Dimitriadis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Norsworthy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bass</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kipps</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Coulthard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Polke</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bernal-Quiros</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Denning</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Raybould</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tabrizi</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Hummerich</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Collinge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series</article-title>
<source/>Mol Psychiatry
          <year>2018</year>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname>
<given-names>ASL</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>E-K</given-names>
</name>
</person-group>
<article-title>Intermediate C9orf72 alleles in neurological disorders: does size really matter?</article-title>
<source/>J Med Genet
          <year>2017</year>
<volume>54</volume>
<issue>9</issue>
<fpage>591</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="pmid">28689190</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Al-Chalabi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hardiman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kiernan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Genetic screening in sporadic ALS and FTD</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2017</year>
<volume>88</volume>
<issue>12</issue>
<fpage>1042</fpage>
<lpage>1044</lpage>
<pub-id pub-id-type="pmid">28642287</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>CJD</given-names>
</name>
<name>
<surname>Volkmer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Bond</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Crutch</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Primary progressive aphasia: a clinical approach</article-title>
<source/>J Neurol
          <year>2018</year>
<volume>265</volume>
<issue>6</issue>
<fpage>1474</fpage>
<lpage>1490</lpage>
<pub-id pub-id-type="pmid">29392464</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacLeod</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tibben</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frontali</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Evers-Kiebooms</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martinez-Descales</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roos</surname>
<given-names>RA</given-names>
</name>
<collab>Editorial C, Working Group ‘Genetic Testing Counselling’ of the European Huntington Disease N</collab>
</person-group>
<article-title>Recommendations for the predictive genetic test in Huntington’s disease</article-title>
<source/>Clin Genet
          <year>2013</year>
<volume>83</volume>
<fpage>221</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="pmid">22642570</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molinuevo</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Pintor</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peri</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lleo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oliva</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Blesa</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Emotional reactions to predictive testing in Alzheimer’s disease and other inherited dementias</article-title>
<source/>Am J Alzheimers Dis Other Demen
          <year>2005</year>
<volume>20</volume>
<fpage>233</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="pmid">16136847</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crook</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>DB</given-names>
</name>
</person-group>
<article-title>Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations</article-title>
<source/>Amyotroph Lateral Scler Frontotempor Degener
          <year>2017</year>
<volume>18</volume>
<fpage>475</fpage>
<lpage>485</lpage>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Genetic testing and counseling in the diagnosis and management of young-onset dementias</article-title>
<source/>Psychiatr Clin N Am
          <year>2015</year>
<volume>38</volume>
<fpage>295</fpage>
<lpage>308</lpage>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheran</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Silverman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Manoochehri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cines</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fallon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Olszewska</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Heidebrink</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shair</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huey</surname>
<given-names>ED</given-names>
</name>
</person-group>
<article-title>Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in <italic>MAPT</italic> mutation carriers</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2018</year>
<volume>89</volume>
<issue>5</issue>
<fpage>449</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">29353234</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Gendron Tania</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Saberi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McAlonis-Downes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seelman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stauffer Jennifer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jafar-nejad</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Drenner</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>S-C</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Engelhardt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baughn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Platoshyn</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Marsala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heyser Charles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ard</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>De Muynck</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Daughrity Lillian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Swing Deborah</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tessarollo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jung Chris</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Delpoux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Utzschneider Daniel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hedrick Stephen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Jong</surname>
<given-names>Pieter J</given-names>
</name>
<name>
<surname>Edbauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Van Damme</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Petrucelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shaw Christopher</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Da Cruz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ravits</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rigo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cleveland Don</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lagier-Tourenne</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs</article-title>
<source/>Neuron
          <year>2016</year>
<volume>90</volume>
<fpage>535</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="pmid">27112497</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeVos</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Schoch</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Kebodeaux</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Wegener</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zanardi</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Kordasiewicz</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Swayze</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy</article-title>
<source/>Sci Transl Med
          <year>2017</year>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arrant</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Onyilo</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Roberson</surname>
<given-names>ED</given-names>
</name>
</person-group>
<article-title>Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis</article-title>
<source/>J Neurosci
          <year>2018</year>
<volume>38</volume>
<issue>9</issue>
<fpage>2341</fpage>
<lpage>2358</lpage>
<pub-id pub-id-type="pmid">29378861</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amado</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Rieders</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Diatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hernandez-Con</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lancaster</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Chen-Plotkin</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>AAV-mediated progranulin delivery to a mouse model of progranulin deficiency causes T cell-mediated toxicity</article-title>
<source/>Mol Ther
          <year>2019</year>
<volume>27</volume>
<issue>2</issue>
<fpage>465</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="pmid">30559071</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jadhav</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Avila</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schöll</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Kövari</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Skrabana</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Kontsekova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Malawska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>de Silva</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Buee</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zilka</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>A walk through tau therapeutic strategies</article-title>
<source/>Acta Neuropathol Commun
          <year>2019</year>
<volume>7</volume>
<issue>1</issue>
<fpage>22</fpage>
<pub-id pub-id-type="pmid">30767766</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prudencio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Caulfield</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Tay</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>PO</given-names>
</name>
<name>
<surname>Chew</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sasaguri</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jansen-West</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Gendron</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Stetler</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Finch</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>FB</given-names>
</name>
<name>
<surname>Petrucelli</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Targeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<issue>6</issue>
<fpage>1467</fpage>
<lpage>1478</lpage>
<pub-id pub-id-type="pmid">24163244</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>She</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kurtser</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Hennig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>WN</given-names>
</name>
<name>
<surname>Mazitschek</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Herz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haggarty</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Selectivity and kinetic requirements of HDAC inhibitors as progranulin enhancers for treating frontotemporal dementia</article-title>
<source/>Cell Chem Biol
          <year>2017</year>
<volume>24</volume>
<issue>7</issue>
<fpage>892</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="pmid">28712747</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>